Avivagen Inc V.VIV

points to a strong 2014.

[DrJayser]

Cameron Groome, CEO and President of Avivagen Inc. (TSX:V.VIV, Stock Forum), has released a corporate update and letter to shareholders that points to a strong 2014.

Groome points out a substantially stronger balance sheet and three product distribution/marketing channels for the company’s OxC Beta-based technology as a demonstration of progress for the company over twelve months prior, and indicates that the focus of the company has moved from the hard work of building customer relationships to now exploiting those relationships to build revenue.

Of particular note is the company push towards the Asian livestock market, where a single sale to a company boasting millions of head of cattle can bring company-making revenues.

“As your CEO and a fellow shareholder, I am very optimistic about the balance of 2014,” said Groome. “During the rest of this year I hope and expect we will formalize a series of clinical trial and customer relationships. This should include Avivagen-sponsored livestock trials intended to result in approvable product claims and customer-sponsored livestock trials that result in sales. We are also working to develop the sales of our Vivamune and Oximunol companion animal product lines. We will report progress as it is achieved and we foresee a relatively full calendar of milestone disclosures.”

Avivagen’s product is touted as a potential replacement for antibiotics in livestock feed, using the OxC Beta technology to help animals fight sickness, grow in size, and improve immunity in a more natural way than traditional methods.
The company also sells companion animal products in the US.

Shares were up 7.69% on the announcement, with above average trading volume.

The company has a market cap of $11.7 million.